-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation Agents

Sponsor: AstraZeneca LP
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Diseases, Therapies, Adverse Events
Friday, December 8, 2023: 3:00 PM-6:00 PM
Ballroom 20CD (San Diego Convention Center)
Shmuel Shoham, MD, Johns Hopkins University School of Medicine
Shoham: Adagio Therapeutics, Inc.; Adamis Pharmaceuticals Corporation; Immunome; Karius, Inc.; Pfizer; and SCYNEXIS, Inc.: Consultancy; Ansun Biopharma; Cidara Therapeutics, Inc.; F2G; Octapharma USA, Inc.; and Zeteo Biomedical LLC.: Research Funding.
Ghady Haidar, MD, University of Pittsburgh and UPMC and Carol Ann Huff, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins School of Medicine
Haidar: AstraZeneca and Karius, Inc.: Consultancy; Allovir; AstraZeneca; Karius, Inc.; and National Institutes of Health (NIH): Research Funding; International AIDS Society and MDOutlook.: Speakers Bureau. Huff: Janssen Pharmaceuticals, Inc. and Sanofi.: Consultancy.
On Demand program will be available here December 13, 2023.

This CME activity is provided by Penn State College of Medicine and developed with our educational partner, PVI, PeerView Institute for Medical Education.

This activity is supported by an independent educational grant from AstraZeneca LP.

Hundreds of thousands of patients with hematologic malignancies in the United States must take medications that leave them immunocompromised. Though vaccinated, these patients have hundred-fold higher rates of serious breakthrough COVID-19 infections compared with healthy individuals because of inadequate responses to vaccination. Tixagevimab/cilgavimab lost its emergency use authorization as prevention for immunocompromised patients because of its lack of efficacy against newer variants. However, next-generation prevention agents are in development, including a new monoclonal antibody, AZD3152. Meanwhile prevention of COVID-19 for immunocompromised people is shifting to a more individualized approach, increasing the complexity of clinical decision-making.

PeerView's expert faculty will discuss strategies to engage patients with elevated risk of serious COVID-19 infection in the development of customized prevention plans. In addition, they will explore approaches to overcoming real-time barriers to access and use of available options for prevention of serious COVID-19 illness.